



Unlocking life-saving treatments potential

“Time is Brain”:
**Every minute until they get
treatment increases the risk**

**Talk, walk, or understand you...
Forever**

Current workflow: requires contrast medical imaging to assess stroke treatment

Basic stroke assessment

Available in every hospital worldwide


Stage 1

Neurological exploration



Stage 2

Non-contrast CT scan




Contrast CT assessment

Not available 24/7 in +50% hospitals worldwide

Stage 3

Contrast CT scan



Stage 4

Stroke Treatment



Methinks goal is to reduce time-to-treatment: enhancing the diagnosis precision of non-contrast CT

Basic stroke assessment

Available in every hospital worldwide

Stage 1


Neurological exploration

Stage 2

Non-contrast CT scan

Stage 4

Stroke Treatment



time saving

Up to 60min

Every minute,
2 million neurons die

Global impact of stroke:
+7,2M people
are diagnosed each year

Methinks could save:

97,308 disabilities

40,392 lives


+ €4,8B to healthcare systems or families



Non-contrast images:
don't show the vascularity
of the brain



Contrast images:
show how blood flows




**Methinks identifies
the location of the clot:
and the affected tissue without
the need for contrast CT**





More than an AI application:
also a communication system

Deep Learning solution



Communication system




Contrast AI solutions are available: and existing non-contrast solutions can't find all kind of clots

Basic stroke assessment


Contrast CT assessment

Not available 24/7 in +50% hospitals worldwide




What is next: maximizing the potential of non-contrast CT

Core assessment from non-contrast CT




Clot type composition from both non-contrast and contrast CT



A disruptive paper: in detecting occlusions from non-contrast CT

Recent publication at AHA Journal



Largest dataset: 1.453 not selected patients

High accuracy (published in 2020):

- With clinical data: (ss=0.83/sp=0.85)
- Without clinical data: (ss=0.83/sp=0.71)

Occlusions: all LVOs (including posterior circulation)



**Awarded in global
AI competition:
with + 1,200 applicants**

**Gold Medal
in the Intracranial Haemorrhage
Detection Competition**



EIT Health Catapult & Gold company: fast-tracking Europe's best start-ups

1st prize Digital Health 2020



Gold Company



Market validation: with top hospitals and channel partners

Working real-time

On boarding pilots

Europe	United States

Letters of Interest


Go-to-market: clinical validations & partnerships

Direct sales: trials + reimbursement

Channel partners: medical devices/imaging corps

Licensing: platforms & partners

Interest in all of these categories



Recently raised €2,1M: to have a market ready product early 2022



Board of Directors: proven track-record



Cristian Martí

Chairman of the Board
CSO & Founder

Founder and CEO/CTO
of Coordina, sold to Tomtom



Pau Rodríguez

Board Member
CEO

'MBA student of the year 2016'
by AMBA sponsored by
Wall Street Journal



Dr. Tudor G. Jovin

Board Member

Chief at Cooper University
Hospital. Leader in key trials
on stroke



Joël Jean-Mairet

Board Member

Founder and MD of Ysios
Capital (€ 345 AuM)



Marc Subirats

Board Member

Founder of Advanced Medical,
sold to Teladoc (€300M)



Other key
investors:



Carlos Gallardo

Board Member at Almirall
CEO – CG Health Ventures

Xavier Rubiralta

Board Member at Werfen
President at Monterri Investments

Advisors: unique understanding of the space



Dr. Luis Donoso
Former President
European Society
of Radiology



Dr. Ángel Chamorro
Former Vice-President
European Stroke Organisation



Dr. Demetrius Lopes
Director Stroke Network
Advocate Aurora Health, US



Tom Neufelder
Former SVP Medical
Imaging Philips



Dr. Joan Bigorra
Former Managing Director
Novartis Spain



Balanced team: focused in unmet clinical needs and engineering excellence



Jordi Pedrol
CFO



Pau Rodríguez
CEO




Marc Ribó
MD, CMO



Cristian Martí
CSO



Carlos Crespo
CTO



Claudia Carbonell
RA&QA specialist



Facundo Díaz
MD, Product Specialist



María Hernandez
MD, Product Specialist



Cristina Granés
Senior Developer



Alba García
Junior Developer



Víctor Salvia
Junior Developer



Andrés Coello
System admin

Key take away:

A **clear** medical need

A validated **commercial interest**

A **unique technology**

The **best team** to make it happen

Join us

Exciting challenges ahead!

Pau Rodríguez
CEO
p.rodriguez@methinks.ai